Alan Mateo bought $446k of TXG
director at 10x Genomics, Inc.. 40,000 shares at an average of $11.14, traded Feb 21, 2025, filed Feb 25, 2025.
Score components
- +15RoleDirector
- +17Trade size$446k at market
- +10Relative to holdingsHoldings up 184%
- +18Price context0% above the 52-week low; 54% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001610717-25-000034, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 21, 2025 | POpen-market purchase Class A Common Stock | +40,000 | $11.14 | $446k | 61,691 | Feb 25, 2025 |
Related signals
Other insiders at 10x Genomics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | 10x Genomics, Inc. | Serge Saxonov Chief Executive Officer | $2.0M 25,000 shares | -2% | |
| 32Weak | 10x Genomics, Inc. | Shehnaaz Suliman director | $465k 5,723 shares | -19% | |
| 47Moderate | 10x Genomics, Inc. | Adam Taich Chief Financial Officer | $3.0M 46,388 shares | -13% | |
| 48Moderate | 10x Genomics, Inc. | John R Stuelpnagel director | $1.2M 20,000 shares | -6% | |
| 40Moderate | 10x Genomics, Inc. | Benjamin J. Hindson See Remarks | $103k 7,486 shares | -2% | |
| 51Moderate | 10x Genomics, Inc. | Adam Taich Chief Financial Officer | $308k 22,315 shares | -7% | |
| 51Moderate | 10x Genomics, Inc. | Serge Saxonov Chief Executive Officer | $129k 9,348 shares | -1% | |
| 43Moderate | 10x Genomics, Inc. | Adam Taich Chief Financial Officer | $34k 4,044 shares | -1% | |
| 37Weak | 10x Genomics, Inc. | Benjamin J. Hindson See Remarks | $62k 7,485 shares | -2% | |
| 49Moderate | 10x Genomics, Inc. | Serge Saxonov Chief Executive Officer | $78k 9,343 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.